MétaCan
Menu
Back to cohort

Ocular Adverse Events With Semaglutide

2025· review· en· W4413139441 on OpenAlexaff
Gabriella Richter da Natividade, Bernardo Frison Spiazzi, Matheus Wohlfahrt Baumgarten, Caroline de Fraga Bassotto, Andréa Z Pereira, Bruna L. Fraga, Bruno G. Scalco, Nicole R. Mattes, Daniel Lavinsky, Caroline K. Kramer, Fernando Gerchman

Bibliographic record

VenueJAMA Ophthalmology · 2025
Typereview
Languageen
FieldMedicine
TopicIntraoperative Neuromonitoring and Anesthetic Effects
Canadian institutionsMount Sinai Hospital
Fundersnot available
KeywordsMedicineSemaglutideMeta-analysisAdverse effectSystematic reviewMEDLINEInternal medicineDiabetes mellitusType 2 diabetes

Abstract

fetched live from OpenAlex

Importance: Semaglutide is a widely used treatment for diabetes and obesity, offering considerable cardiovascular benefit. However, its association with ocular adverse events remains uncertain. Objective: To assess the incidence of eye disorders, diabetic retinopathy, and nonarteritic anterior ischemic optic neuropathy (NAION) in adults treated with semaglutide. Data Sources: A comprehensive electronic search of PubMed, Embase, and the Cochrane Central Register of Controlled Trials was conducted on April 10, 2025, without date restrictions. Study Selection: Investigators independently screened records to identify randomized clinical trials comparing semaglutide with either an active comparator or placebo in adults, assessing ocular adverse events. Data Extraction and Synthesis: Descriptive synthesis of the included studies was performed. The random-effects model using the inverse variance method was used to summarize the odds ratio (OR) for eye disorders and diabetic retinopathy. Peto OR with a fixed-effects model was applied for NAION. Risk of bias was assessed with the RoB 2.0 tool and quality of evidence with GRADE. Trial sequential analysis (TSA) was performed to determine whether the available data were sufficient for definitive conclusions. Main Outcomes and Measures: The primary outcomes included the number of patients experiencing an ocular adverse event, diabetic retinopathy, or NAION. Subgroup analyses were conducted based on follow-up duration, comparator type, and primary baseline condition. Results: A total of 78 trials with 73 640 participants were included. Semaglutide did not increase or reduce the risk of eye disorders (OR, 1.01; 95% CI, 0.91-1.12) or diabetic retinopathy (OR, 1.04; 95% CI, 0.92-1.17). Treatment with semaglutide was associated with a significant odds of NAION (OR, 3.92; 95% CI, 1.02-15.02). Overall risk of bias was low. TSA provided evidence that the sample size was sufficient to avoid missing alternative results for diabetic retinopathy but not for NAION. Conclusions and Relevance: These findings suggest that semaglutide was not associated with an increased risk of eye disorders or diabetic retinopathy. Despite the fact that an association between semaglutide treatment and NAION was found, current evidence remains insufficient to establish definitive conclusions regarding its association with NAION. Further studies with larger sample sizes and adequate evaluation of NAION are warranted to clarify this potential risk.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.007
metaresearch head score (Gemma)0.021
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Systematic review · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.007
Threshold uncertainty score0.039

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0070.021
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0020.006
Bibliometrics0.0020.002
Science and technology studies0.0000.001
Scholarly communication0.0020.001
Open science0.0010.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0050.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.029
GPT teacher head0.363
Teacher spread0.334 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designSystematic review
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations24
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueJAMA OphthalmologySame topicIntraoperative Neuromonitoring and Anesthetic EffectsFrench-language works237,207